Sam Brusco, Associate Editor09.01.23
Globus Medical has completed the $3.1 billion merger deal with fellow orthopedic giant NuVasive. The deal was first announced in February of this year.
“We’re thrilled to begin our journey together to create a leading global musculoskeletal company,” Dan Scavilla, president and CEO of Globus Medical told the press. “With a relentless focus on changing patient lives, we’re combining our differentiated portfolios and talented teams to reach more customers as we advance spine and orthopedic care globally.”
The merger combines Globus and NuVasive’s complementary global scale, expanded commercial reach, comprehensive spine and orthopedic portfolios, product development and surgeon education, and increased operational capabilities.
“Our combination with NuVasive is a defining moment in our company's history,” said David Paul, executive chairman of Globus Medical. “I’m incredibly proud of the strong legacy we’ve built at Globus Medical, and I look forward to delivering on the many opportunities for our surgeon customers and their patients as a combined company.”
"The combination with Globus Medical is highly transformative—bringing together two leading companies with a shared vision to change the lives of more patients around the globe,” said Chris Barry, former CEO of NuVasive. "I look forward to helping the combined organization transform the future of surgery.”
Following the transaction’s close, Globus approved expansion of its board of directors from eight to 11 directors and named three NuVasive board members to the Globus board, effective immediately: John DeFord, Ph.D., Leslie V. Norwalk, Esq., and Daniel J. Wolterman.
NuVasive common stock ceased trading on the Nasdaq as of the close of trading on August 31.
“We’re thrilled to begin our journey together to create a leading global musculoskeletal company,” Dan Scavilla, president and CEO of Globus Medical told the press. “With a relentless focus on changing patient lives, we’re combining our differentiated portfolios and talented teams to reach more customers as we advance spine and orthopedic care globally.”
The merger combines Globus and NuVasive’s complementary global scale, expanded commercial reach, comprehensive spine and orthopedic portfolios, product development and surgeon education, and increased operational capabilities.
“Our combination with NuVasive is a defining moment in our company's history,” said David Paul, executive chairman of Globus Medical. “I’m incredibly proud of the strong legacy we’ve built at Globus Medical, and I look forward to delivering on the many opportunities for our surgeon customers and their patients as a combined company.”
"The combination with Globus Medical is highly transformative—bringing together two leading companies with a shared vision to change the lives of more patients around the globe,” said Chris Barry, former CEO of NuVasive. "I look forward to helping the combined organization transform the future of surgery.”
Following the transaction’s close, Globus approved expansion of its board of directors from eight to 11 directors and named three NuVasive board members to the Globus board, effective immediately: John DeFord, Ph.D., Leslie V. Norwalk, Esq., and Daniel J. Wolterman.
NuVasive common stock ceased trading on the Nasdaq as of the close of trading on August 31.